Top Abstract Purchase Related
Home
>
Node
>
Subnode

The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient

Toi, M.; Taniguchi, T.; Hayashi, K.; Tominaga, T.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(6): 799-804

1995

ISSN/ISBN: 0385-0684
PMID: 7755388
Document Number: 450951
The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients. Out of 20 patients, 8(40.0%) responded to the treatment. The average duration of response was 10.3 months. Response rates stratified by recurrence site were soft tissues 36.4%, bone 44.4%, liver 60.0% and lung 20.0%, respectively. No serious side effect except body weight gain, which was caused by MPA, was seen. In a 76-year-old woman with liver metastases, a marked response was obtained and has continued for more than 24 months. It was suggested that the combination of 5'-DFUR and MPA may be effective for recurrent breast cancer patients.

Document emailed within 1 workday
Secure & encrypted payments

Takatsuka, Y.; Katoh, T.; Tsumura, I.; Kobayakawa, K.; Kawahara, T. 1992: Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(1): 107-110
Iba, T.; Kidokoro, A.; Fukunaga, M.; Sugiyama, K.; Aihara, N.; Suda, M. 2001: The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(7): 973-977
Kihara, M.; Kontani, K.; Yamauchi, A.; Yokomise, H. 2005: Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(5): 683-686
Sonoo, H.; Senoo, T.; Nishiki, M.; Morimoto, T.; Takashima, S. 1996: Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(4): 447-454
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Mitsuyama, S.; Kuroda, Y.; Ohsato, K.; Nakamura, Y.; Murakami, F.; Nishikata, F.; Ikeda, S.; Egami, T.; Mori, A.; Ohe, H. 1996: Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1153-1160
Sica, G.; Lama, G.; Iacopino, F.; Angelucći, C.; Della Cuna, G.R.; Marchetti, P. 1991: Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells Anticancer Research 11(6): 2099-2102
Pannuti, F.; Di Marco, A.R.; Martoni, A.; Fruet, F.; Strocchi, E.; Burroni, P.; Marraro, D. 1982: Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages Minerva Ginecologica 34(11): 977-979
Guarnieri, A.; Tucci, E.; D'Aniello, C.; Carli, A.; Mariani, L.; De Stefano, A.; Nardi, P. 1984: Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 3(5): 320-323
Kaunitz, A.M. 1996: Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer Journal of Reproductive Medicine 41(5 Suppl): 419-427
Lorenz, I.; Mechl, Z. 1985: Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer Neoplasma 32(1): 119-124
Møller, K.A.; Andersen, A.P. 1981: Peroral administration of medroxyprogesterone acetate (MPA) in advanced cancer of the breast. A preliminary report Acta obstetricia et gynecologica Scandinavica. Supplement 101: 47-48
Sumimura, J.; Morimoto, Y.; Miyazaki, M.; Ishikawa, S.; Nagai, I. 1999: Comparative study of 5'-deoxy-5-fluorouridine between older cancer patients versus younger cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(4): 561-564
Zhang, J.; Mizoi, T.; Harada, N.; Shiiba, K-Ichi.; Miyagawa, K.; Matsuno, S.; Sasaki, I. 2003: Thymidine phosphorylase expressed in macrophages enhances antitumor effect of 5'-deoxy-5-fluorouridine on human colorectal carcinoma cells Anticancer Research 23(1a): 323-329
Klaassen, D.J.; Rapp, E.F.; Hirte, W.E. 1976: Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women Cancer Treatment Reports 60(3): 251-253
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518
Kaira, K.; Ishizuka, T.; Yanagitani, N.; Sunaga, N.; Hisada, T.; Mori, M. 2007: Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(2): 225-227
Mantovani, G.; Macciò, A.; Lai, P.; Massa, E.; Ghiani, M.; Santona, M.C. 1998: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate Seminars in Oncology 25(2 Suppl 6: 45-52